ABSTRACTS from 16th International COnference on ... - CRRT Online

<strong>ABSTRACTS</strong> FROM 17 TH INTERNATIONAL CONFERENCE ON CRRT,
SAN DIEGO, FEB 14-17, 2012
Median estimated glomerular filtration
rate based on serum creatinine (updated
Schwartz formula) ranged <strong>from</strong> 19 – 24
ml/min/1.73m2, and median effluent rate
ranged <strong>from</strong> 1832 – 2877
ml/min/1.73m2 (Q3 of 2327 – 497
ml/min/1.73m2) between age groups. T
> MIC was decreased in younger age
groups, but adequate for children above
15 years of age. Q3 effluent rates caused
a 6 -14% reduction in T > MIC. (See
table). Conclusion: Extracorporeal
clearance and high effluent rates may
render MP dosing recommendations of 2
mg/kg inadequate for younger age
groups receiving CRRT. These in silico
PK/PD models will need to be verified
prospectively in children receiving MP
and CRRT.
Age
Group
< 1
year
1-5
years
5-1
years
1-15
years
> 15
years
Median
Weight
(kg)
T > MIC
(median
effluent
rate)
T > MIC
(Q3
effluent
rate)
3.6 38% 28%
13.8 58% 52%
24.2 62% 52%
45. 88% 74%
59.9 94% 82%
16. Evaluation of the Potential
Adverse Effects Associated with
Calcium Carbonate Precipitate
During Continuous Veno-Venous
Hemofiltration (CVVH)
David S Pantaleone, Benjamin Brooks,
Justin Daller, Jerome Gass, Jeffrey
McKee, Paul Zieske, Paola Mussi,
Benoit Moreaux
Baxter Healthcare Corporation
Purpose: This study evaluated the
potential adverse effects associated with
exposure to calcium carbonate
precipitate in Accusol 35 Solution
(Accusol 35) during CVVH. The clinical
use of Accusol 35 has been associated
with occasional formation of calcium
carbonate precipitate in the tubing set
during therapy. Methods: 14 dogs were
anesthetized, instrumented, and received
CVVH with the test (6) or negative
control article (8) for 6 hr. The test
article was Accusol 35 with induced
precipitate formation prior to CVVH,
containing visible particles and subvisible
particles 36X higher than the
maximum concentration specified in
European Pharmacopoeia (EP). The
negative control article was Accusol 35
conforming to EP specification. Onehalf
the dogs in the negative control
article group received a central venous
injection of Sephadex G-5 beads (1
mg/kg) following CVVH as positive
control. Select cardiovascular (CV)
parameters (systemic and pulmonary
arterial pressures, central venous
pressure, heart rate and cardiac output)
were monitored continuously, and stroke
volume and systemic and pulmonary
vascular resistances were calculated at
pre-determined times throughout CVVH.
Arterial samples were obtained for blood
gas analysis. Samples of the test and
negative control articles were obtained
hourly during CVVH for determination
134